Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Average Price Target of $107.44 According to Analysts

Posted by George Bondi on Oct 31st, 2026

Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) has received a consensus recommendation of “Hold” from the fourteen ratings firms that are currently covering the firm, MarketBeat reports. Eleven equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $107.44.

A number of equities research analysts have commented on the stock. Mizuho lowered shares of Lantheus from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $115.00 to $109.00 in a report on Tuesday, October 13th. Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. Leerink Partners set a $102.50 price objective on Lantheus in a research note on Monday, August 3rd. Weiss Ratings cut Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 15th. Finally, CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th.

Check Out Our Latest Stock Analysis on Lantheus

Lantheus Price Performance

NASDAQ LNTH opened at $100.46 on Monday. The stock’s 50-day moving average is $100.26 and its two-hundred day moving average is $91.17. Lantheus has a fifty-two week low of $50.15 and a fifty-two week high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The firm has a market cap of $6.56 billion, a P/E ratio of 20.15 and a beta of -0.06.

Lantheus (NASDAQ:LNTH – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.57 earnings per share. On average, analysts anticipate that Lantheus will post 4.54 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Several hedge funds have recently added to or reduced their stakes in LNTH. Oregon Public Employees Retirement Fund increased its position in Lantheus by 0.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 13,559 shares of the medical equipment provider’s stock worth $1,350,000 after purchasing an additional 100 shares during the period. GAMMA Investing LLC boosted its holdings in Lantheus by 3.3% during the third quarter. GAMMA Investing LLC now owns 3,457 shares of the medical equipment provider’s stock worth $344,000 after purchasing an additional 109 shares during the last quarter. ABS Investment Management LLC acquired a new stake in Lantheus in the second quarter valued at $232,974,000. Versant Capital Management Inc raised its stake in Lantheus by 33.0% in the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after acquiring an additional 146 shares during the period. Finally, Abel Hall LLC grew its position in shares of Lantheus by 4.6% in the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after purchasing an additional 172 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

(Get Free Report)

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.